JW Pharmaceutical Corporation

KSE 001060.KS

JW Pharmaceutical Corporation EBITDA Margin for the year ending December 31, 2023: 11.92%

JW Pharmaceutical Corporation EBITDA Margin is 11.92% for the year ending December 31, 2023, a 11.05% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

JW Pharmaceutical Corporation EBITDA Margin for the year ending December 31, 2022 was 10.73%, a 44.27% change year over year.
JW Pharmaceutical Corporation EBITDA Margin for the year ending December 31, 2021 was 7.44%, a 170.21% change year over year.
JW Pharmaceutical Corporation EBITDA Margin for the year ending December 31, 2020 was 2.75%, a 590.96% change year over year.
JW Pharmaceutical Corporation EBITDA Margin for the year ending December 31, 2019 was -0.56%, a -107.66% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KSE: 001060.KS

JW Pharmaceutical Corporation

CEO	Mr. Young-Sub Shin
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	2477, Nambusunhwan-ro
Employees	1,064
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care

Description

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years